MedElevator Войти в исследования
← Поиск публикаций

DOI 10.2967/jnumed.115.158253

Медицинская библиотека · Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2015

Multicenter Reproducibility of 18F-Fluciclatide PET Imaging in Subjects with Solid Tumors.

Sharma Rohini, Kallur Kumar G, Ryu Jin S, Parameswaran Ramanathapuram V, Lindman Henrik, Avril Norbert, Gleeson Fergus V, Lee Jong D, Lee Kyung-Han, O'Doherty Michael J, Groves Ashley M, Miller Matthew P, Somer Edward J, Coombes Charles R, Aboagye Eric O

СтатьяМногоцентровое исследованиеПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

UNLABELLED: Integrins are upregulated on both tumor cells and associated vasculature, where they play an important role in angiogenesis and metastasis. Fluciclatide is an arginine-glycine-aspartic acid peptide with high affinity for αvβ3/αvβ5 integrin, which can be radiolabeled for PET imaging of angiogenesis. Thus, (18)F-fluciclatide is a potential biomarker of therapeutic response to antiangiogenic inhibitors. The aim of this study was to evaluate the reproducibility of (18)F-fluciclatide in multiple solid-tumor types.

METHODS

Thirty-nine patients underwent PET/CT scanning at 40, 65, and 90 min after injection of (18)F-fluciclatide (maximum, 370 MBq) on 2 separate days (2-9 d apart). Patients did not receive any therapy between PET/CT scans. (18)F-fluciclatide images were reported and quantitative measures of uptake were extracted using the PERCIST methodology. Intrasubject reproducibility of PET uptake in all measurable lesions was evaluated by calculating relative differences in SUV between PET scans for each lesion during the 2 imaging sessions.

RESULTS

Thirty-nine measurable lesions were detected in 26 patients. Lesion uptake correlated strongly across imaging sessions (r = 0.92, P < 0.05, at 40 min; r = 0.94, P < 0.05, at 65 min; r = 0.94, P < 0.05, at 90 min) with a mean relative difference and SD of the relative difference of 0.006 ± 0.18 at 40 min, 0.003 ± 0.19 at 65 min, and 0.025 ± 0.20 at 90 min. This reflects 95% limits of repeatability of 35%-39% for the difference between the 2 SUV measurements or a variability of 18%-20% in agreement from that observed in well-calibrated multicenter (18)F-FDG studies.

CONCLUSION

The test-retest reproducibility of (18)F-fluciclatide across multiple tumor types has been measured and shown to be acceptable. This is an important step in the development of this in vivo biomarker to identify and quantify response to antiangiogenic therapy in cancer patients.

Для цитирования: Sharma Rohini, Kallur Kumar G, Ryu Jin S, Parameswaran Ramanathapuram V, Lindman Henrik, Avril Norbert, Gleeson Fergus V, Lee Jong D, Lee Kyung-Han, O'Doherty Michael J, Groves Ashley M, Miller Matthew P, Somer Edward J, Coombes Charles R, Aboagye Eric O. Multicenter Reproducibility of 18F-Fluciclatide PET Imaging in Subjects with Solid Tumors.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2015. DOI: 10.2967/jnumed.115.158253.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.